Anti-Coagulants - Jamaica

Jamaica

Highlights

The revenue in the Anti-Coagulants market in Jamaica is estimated to reach US$2.74m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 7.06%, leading to a market volume of US$3.86m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue, amounting to US$16.74bn in 2024.
Jamaica's growing elderly population and increasing prevalence of cardiovascular diseases are driving the demand for anti-coagulants in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Anti-Coagulants in Jamaica has been on the rise in recent years.

Customer preferences: Patients in Jamaica have shown a preference for Anti-Coagulants due to its effectiveness in reducing the risk of blood clots and preventing strokes. Additionally, the aging population in Jamaica has contributed to the growth of the Anti-Coagulants market as the risk of developing blood clots and strokes increases with age.

Trends in the market: The Anti-Coagulants market in Jamaica has experienced steady growth due to the increasing prevalence of cardiovascular diseases. The market has also seen a shift towards the use of newer oral Anti-Coagulants as they offer a more convenient and effective alternative to traditional Anti-Coagulants such as warfarin. Furthermore, the introduction of generic Anti-Coagulants in Jamaica has increased competition in the market, leading to a decrease in prices.

Local special circumstances: Jamaica has a high incidence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. Additionally, the Jamaican government has implemented policies to improve access to healthcare, which has led to an increase in the number of patients seeking treatment for cardiovascular diseases. However, the high cost of Anti-Coagulants in Jamaica remains a barrier to access for some patients.

Underlying macroeconomic factors: Jamaica's economy has been growing in recent years, which has led to an increase in the number of people with disposable income. This has contributed to the growth of the Anti-Coagulants market as patients are able to afford the high cost of treatment. Additionally, the Jamaican government has implemented policies to attract foreign investment, which has led to an increase in the availability of healthcare resources and infrastructure.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.